{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:43:04Z","timestamp":1765838584623,"version":"3.48.0"},"reference-count":41,"publisher":"BMJ","issue":"7","funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,6,1]]},"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Antibiotic overuse drives antibiotic resistance. The optimal duration of antibiotic therapy for Gram-negative bacteraemia (GNB), a common community and hospital-associated infection, remains unknown and unstudied via randomised controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This investigator-initiated, multicentre, non-inferiority, informatics-based point-of-care RCT will randomly assign adult hospitalised patients receiving microbiologically efficacious antibiotic(s) for GNB to (1) 14 days of antibiotic therapy, (2) 7\u2009days of therapy or (3) an individualised duration determined by clinical response and 75% reduction in peak C reactive protein (CRP) values. The randomisation will occur in equal proportions (1:1:1) on day 5 (\u00b11) of efficacious antibiotic therapy as determined by antibiogram; patients, their physicians and study investigators will be blind to treatment duration allocation until the day of antibiotic discontinuation. Immunosuppressed patients and those with GNB due to complicated infections (endocarditis, osteomyelitis, etc) and\/or non-fermenting bacilli (\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      spp,\n                      <jats:italic>Burkholderia<\/jats:italic>\n                      spp,\n                      <jats:italic>Pseudomonas<\/jats:italic>\n                      spp)\n                      <jats:italic>Brucella<\/jats:italic>\n                      spp,\n                      <jats:italic>Fusobacterium<\/jats:italic>\n                      spp or polymicrobial growth with Gram-positive organisms will be ineligible. The primary outcome is incidence of clinical failure at day 30; secondary outcomes include clinical failure, all-cause mortality and incidence of\n                      <jats:italic>Clostridiumdifficile<\/jats:italic>\n                      infection in the 90-day study period. An interim safety analysis will be performed after the first 150 patients have been followed for \u226430 days. Given a chosen margin of 10%, the required sample size to determine non-inferiority is roughly 500 patients. Analyses will be performed on both intention-to-treat and per-protocol populations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethics approval was obtained from the cantonal ethics committees of all three participating sites. Results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      This trial is registered at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link>\n                      (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03101072\">NCT03101072<\/jats:ext-link>\n                      ; pre-results).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-017996","type":"journal-article","created":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T20:10:17Z","timestamp":1500063017000},"page":"e017996","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["PIRATE project: point-of-care, informatics-based randomised controlled trial for decreasing overuse of antibiotic therapy in Gram-negative bacteraemia"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct03101072","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Angela","family":"Huttner","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland"},{"name":"Infection Control Program, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner C","family":"Albrich","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St Gallen, St Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Bochud","sequence":"additional","affiliation":[{"name":"Department of Medicine, Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e8le","family":"Gayet-Ageron","sequence":"additional","affiliation":[{"name":"CRC & Division of Clinical Epidemiology, Department of Health and Community Medicine, University Hospitals Geneva, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Rossel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie von","family":"Dach","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland"},{"name":"Infection Control Program, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Harbarth","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland"},{"name":"Infection Control Program, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,7,13]]},"reference":[{"key":"2025121514405641000_7.7.e017996.1","doi-asserted-by":"publisher","DOI":"10.1186\/2047-2994-2-31"},{"key":"2025121514405641000_7.7.e017996.2","unstructured":"WHO Antimicrobial Fact Sheet. 2015 http:\/\/www.who.int\/mediacentre\/factsheets\/fs194\/en\/."},{"key":"2025121514405641000_7.7.e017996.3","unstructured":"Swiss Federal Office of Public Health: responses to the antimicrobial resistance threat. 2015 http:\/\/www.bag.admin.ch\/themen\/internationales\/11287\/."},{"key":"2025121514405641000_7.7.e017996.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00473-0"},{"key":"2025121514405641000_7.7.e017996.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03514.x"},{"key":"2025121514405641000_7.7.e017996.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.19.2588"},{"key":"2025121514405641000_7.7.e017996.7","doi-asserted-by":"publisher","DOI":"10.1186\/cc10545"},{"key":"2025121514405641000_7.7.e017996.8","doi-asserted-by":"publisher","DOI":"10.1086\/599376"},{"key":"2025121514405641000_7.7.e017996.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60608-4"},{"key":"2025121514405641000_7.7.e017996.10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh356"},{"key":"2025121514405641000_7.7.e017996.11","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm119"},{"key":"2025121514405641000_7.7.e017996.12","doi-asserted-by":"publisher","DOI":"10.1086\/377539"},{"key":"2025121514405641000_7.7.e017996.13","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/0016-5085(91)90677-D","article-title":"Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients","volume":"100","author":"Runyon","year":"1991","journal-title":"Gastroenterology"},{"key":"2025121514405641000_7.7.e017996.14","first-page":"284","article-title":"Short course of antibiotic treatment in spontaneous bacterial peritonitis: a randomized controlled study","volume":"10","author":"Chaudry","year":"2000","journal-title":"Journal of the College of Physicians and Surgeons Pakistan"},{"key":"2025121514405641000_7.7.e017996.15","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.15.1669"},{"key":"2025121514405641000_7.7.e017996.16","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31828e969f"},{"key":"2025121514405641000_7.7.e017996.17","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/bjs.9756","article-title":"Meta-analysis of the predictive value of C-reactive protein for infectious complications in abdominal surgery","volume":"102","author":"Adamina","year":"2015","journal-title":"Br J Surg"},{"key":"2025121514405641000_7.7.e017996.18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.diagmicrobio.2014.03.029","article-title":"Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: a systematic review and meta-analysis","volume":"80","author":"Lin","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025121514405641000_7.7.e017996.19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1315638"},{"key":"2025121514405641000_7.7.e017996.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200708-1238OC"},{"key":"2025121514405641000_7.7.e017996.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70323-7"},{"key":"2025121514405641000_7.7.e017996.22","doi-asserted-by":"crossref","first-page":"w13124","DOI":"10.4414\/smw.2010.13124","article-title":"Postoperative serum pro-calcitonin and C-reactive protein levels in patients with orthopedic infections","volume":"140","author":"U\u00e7kay","year":"2010","journal-title":"Swiss Med Wkly"},{"key":"2025121514405641000_7.7.e017996.23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1155\/2013\/141989","article-title":"Duration of antibiotic therapy for critically ill patients with bloodstream infections: A retrospective cohort study","volume":"24","author":"Havey","year":"2013","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2025121514405641000_7.7.e017996.24","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh416"},{"key":"2025121514405641000_7.7.e017996.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61879-1"},{"key":"2025121514405641000_7.7.e017996.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00053-0"},{"key":"2025121514405641000_7.7.e017996.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-015-3978-8"},{"key":"2025121514405641000_7.7.e017996.28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis464"},{"key":"2025121514405641000_7.7.e017996.29","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00016-12"},{"key":"2025121514405641000_7.7.e017996.30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cmi.2015.10.034","article-title":"Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitals","volume":"22","author":"Fitzpatrick","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2025121514405641000_7.7.e017996.31","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/CCM.0000000000001730","article-title":"A framework for the Development and Interpretation of Different Sepsis definitions and clinical criteria","volume":"44","author":"Angus","year":"2016","journal-title":"Crit Care Med"},{"key":"2025121514405641000_7.7.e017996.32","doi-asserted-by":"publisher","DOI":"10.1007\/BF02000400"},{"key":"2025121514405641000_7.7.e017996.33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7523"},{"key":"2025121514405641000_7.7.e017996.34","unstructured":"Food & Drug Administration. Guidance for Industry. E9 Statistical Principles for Clinical Trials 1998 http:\/\/www.fda.gov\/downloads\/drugs\/.\/guidances\/ucm073137.pdf."},{"key":"2025121514405641000_7.7.e017996.35","doi-asserted-by":"publisher","DOI":"10.1186\/cc5120"},{"key":"2025121514405641000_7.7.e017996.36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008838","article-title":"External validity of a randomised controlled trial on the treatment of severe infections caused by MRSA","volume":"5","author":"Paul","year":"2015","journal-title":"BMJ Open"},{"key":"2025121514405641000_7.7.e017996.37","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e318277dd7d"},{"key":"2025121514405641000_7.7.e017996.38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ejhg.2016.132","article-title":"Biobank attributes associated with higher patient participation: a randomized study","volume":"25","author":"Gayet-Ageron","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"2025121514405641000_7.7.e017996.39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/pds.992","article-title":"Recruitment of a cohort of lamotrigine users through community pharmacists: differences between patients who gave informed consent and those who did not","volume":"14","author":"Knoester","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121514405641000_7.7.e017996.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2011.03.007"},{"key":"2025121514405641000_7.7.e017996.41","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-7-18"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-017996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:41:03Z","timestamp":1765838463000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-017996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,13]]},"published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1136\/bmjopen-2017-017996"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-017996","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}